Immuron Limited (IMC.AX)
AUD 0.08
(-3.7%)
AUD 0.08
(-3.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -6.19 Million AUD | -63.1% |
| 2023 | -3.79 Million AUD | -47.59% |
| 2022 | -3.07 Million AUD | 51.83% |
| 2021 | -8.32 Million AUD | -150.14% |
| 2020 | -3.16 Million AUD | 28.84% |
| 2019 | -4.7 Million AUD | -45.08% |
| 2018 | -3.24 Million AUD | 61.36% |
| 2017 | -8.35 Million AUD | -1.54% |
| 2016 | -8.26 Million AUD | -93.08% |
| 2015 | -4.27 Million AUD | -98.91% |
| 2014 | -2.15 Million AUD | 2.33% |
| 2013 | -2.38 Million AUD | -4.2% |
| 2012 | -2.36 Million AUD | 24.11% |
| 2011 | -2.78 Million AUD | -27.45% |
| 2010 | -2.12 Million AUD | 22.31% |
| 2009 | -2.81 Million AUD | 27.99% |
| 2008 | -3.9 Million AUD | 12.1% |
| 2007 | -4.44 Million AUD | 9.33% |
| 2006 | -4.19 Million AUD | -239.43% |
| 2005 | -1.48 Million AUD | -10.32% |
| 2004 | -1.91 Million AUD | 0.0% |
| 2003 | - AUD | 100.0% |
| 2002 | -1.73 Million AUD | 7.22% |
| 2001 | -1.87 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - AUD | -69.36% |
| 2024 Q2 | -1.85 Million AUD | 0.0% |
| 2024 Q4 | -3.35 Million AUD | 0.0% |
| 2023 FY | - AUD | -47.59% |
| 2023 Q2 | -1.86 Million AUD | 0.0% |
| 2023 Q4 | -1.53 Million AUD | 0.0% |
| 2022 Q4 | -1.04 Million AUD | 0.0% |
| 2022 Q2 | -1.9 Million AUD | 0.0% |
| 2022 FY | - AUD | 51.83% |
| 2021 Q2 | -550.9 Thousand AUD | 0.0% |
| 2021 FY | - AUD | -150.14% |
| 2021 Q4 | -7.95 Million AUD | 0.0% |
| 2020 Q2 | -2.54 Million AUD | 0.0% |
| 2020 FY | - AUD | 28.84% |
| 2020 Q4 | -1.56 Million AUD | 0.0% |
| 2019 FY | - AUD | -45.08% |
| 2019 Q4 | -3.32 Million AUD | 0.0% |
| 2019 Q2 | -1.57 Million AUD | 0.0% |
| 2018 Q4 | 31.25 Thousand AUD | 0.0% |
| 2018 Q2 | -3.27 Million AUD | 0.0% |
| 2018 FY | - AUD | 61.36% |
| 2017 Q4 | -4.17 Million AUD | 0.0% |
| 2017 FY | - AUD | -1.54% |
| 2017 Q2 | -4.21 Million AUD | 0.0% |
| 2016 Q4 | -4.43 Million AUD | 0.0% |
| 2016 Q2 | -3.82 Million AUD | 0.0% |
| 2016 FY | - AUD | -93.08% |
| 2015 Q4 | -2.9 Million AUD | 0.0% |
| 2015 Q2 | -1.36 Million AUD | 0.0% |
| 2015 FY | - AUD | -98.91% |
| 2014 Q2 | -1.06 Million AUD | 0.0% |
| 2014 FY | - AUD | 2.33% |
| 2014 Q4 | -960.81 Thousand AUD | 0.0% |
| 2013 Q3 | -550.64 Thousand AUD | 47.11% |
| 2013 FY | - AUD | -4.2% |
| 2013 Q1 | -528.46 Thousand AUD | 0.0% |
| 2013 Q4 | -1.46 Million AUD | -166.19% |
| 2013 Q2 | -1.04 Million AUD | -97.0% |
| 2012 Q1 | -696.37 Thousand AUD | 0.0% |
| 2012 FY | - AUD | 24.11% |
| 2012 Q4 | -528.46 Thousand AUD | 0.0% |
| 2012 Q3 | -528.46 Thousand AUD | 0.0% |
| 2012 Q2 | -528.46 Thousand AUD | 24.11% |
| 2011 Q3 | -696.37 Thousand AUD | 0.0% |
| 2011 Q4 | -696.37 Thousand AUD | 0.0% |
| 2011 FY | - AUD | -27.45% |
| 2011 Q2 | -696.37 Thousand AUD | -31.18% |
| 2011 Q1 | -530.85 Thousand AUD | 0.0% |
| 2010 Q3 | -530.85 Thousand AUD | 0.0% |
| 2010 FY | - AUD | 22.31% |
| 2010 Q4 | -530.85 Thousand AUD | 0.0% |
| 2010 Q2 | -530.85 Thousand AUD | -1.87% |
| 2010 Q1 | -521.12 Thousand AUD | 0.0% |
| 2009 FY | - AUD | 27.99% |
| 2009 Q1 | -759.12 Thousand AUD | 0.0% |
| 2009 Q2 | -521.12 Thousand AUD | 31.35% |
| 2009 Q3 | -521.12 Thousand AUD | 0.0% |
| 2009 Q4 | -521.12 Thousand AUD | 0.0% |
| 2008 Q1 | -851.76 Thousand AUD | 0.0% |
| 2008 Q2 | -759.12 Thousand AUD | 10.88% |
| 2008 FY | - AUD | 12.1% |
| 2008 Q4 | -759.12 Thousand AUD | 0.0% |
| 2008 Q3 | -759.12 Thousand AUD | 0.0% |
| 2007 Q1 | -846.43 Thousand AUD | 0.0% |
| 2007 FY | - AUD | 9.33% |
| 2007 Q2 | -851.76 Thousand AUD | -0.63% |
| 2007 Q4 | -851.76 Thousand AUD | 0.0% |
| 2007 Q3 | -851.76 Thousand AUD | 0.0% |
| 2006 Q2 | -846.43 Thousand AUD | -134.45% |
| 2006 Q1 | -361.02 Thousand AUD | 0.0% |
| 2006 Q4 | -846.43 Thousand AUD | 0.0% |
| 2006 Q3 | -846.43 Thousand AUD | 0.0% |
| 2006 FY | - AUD | -239.43% |
| 2005 Q2 | -361.02 Thousand AUD | -10.32% |
| 2005 FY | - AUD | -10.32% |
| 2005 Q4 | -361.02 Thousand AUD | 0.0% |
| 2005 Q3 | -361.02 Thousand AUD | 0.0% |
| 2005 Q1 | -327.25 Thousand AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2004 Q2 | -327.25 Thousand AUD | 0.0% |
| 2004 Q3 | -327.25 Thousand AUD | 0.0% |
| 2004 Q4 | -327.25 Thousand AUD | 0.0% |
| 2004 Q1 | - AUD | 0.0% |
| 2003 Q1 | -382.5 Thousand AUD | 0.0% |
| 2003 Q2 | - AUD | 100.0% |
| 2003 Q3 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | 100.0% |
| 2002 Q1 | -376.75 Thousand AUD | 0.0% |
| 2002 Q4 | -382.5 Thousand AUD | 0.0% |
| 2002 Q3 | -382.5 Thousand AUD | 0.0% |
| 2002 Q2 | -382.5 Thousand AUD | -1.53% |
| 2002 FY | - AUD | 7.22% |
| 2001 Q3 | -376.75 Thousand AUD | 0.0% |
| 2001 Q4 | -376.75 Thousand AUD | 0.0% |
| 2001 Q2 | -376.75 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 159.683% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -325.105% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 83.007% |
| Biome Australia Limited | -1.57 Million AUD | -292.356% |
| Patrys Limited | -3.49 Million AUD | -77.322% |
| Orthocell Limited | -11.68 Million AUD | 46.988% |
| Imugene Limited | -147.97 Million AUD | 95.815% |
| Noxopharm Limited | -5.94 Million AUD | -4.152% |
| PYC Therapeutics Limited | -38.11 Million AUD | 83.755% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 45.199% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 13.824% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 21.49% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 37.767% |
| CSL Limited | 4.73 Billion AUD | 100.131% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 29.896% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -108.147% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 111.94% |
| Starpharma Holdings Limited | -12.57 Million AUD | 50.764% |
| Nanollose Limited | -1.14 Million AUD | -439.45% |
| Memphasys Limited | -3.3 Million AUD | -87.209% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -759.523% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -244.731% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -35.809% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 55.513% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -119.734% |
| Race Oncology Limited | -14.2 Million AUD | 56.402% |
| Nyrada Inc. | -4.59 Million AUD | -34.728% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 126.963% |
| Dimerix Limited | -24.95 Million AUD | 75.189% |
| PharmAust Limited | -9.45 Million AUD | 34.484% |
| Immutep Limited | -42.87 Million AUD | 85.557% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 86.131% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 68.361% |
| BTC Health Limited | 1.05 Million AUD | 686.794% |
| Acrux Limited | -7.93 Million AUD | 21.922% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 103.108% |
| Biotron Limited | -5.04 Million AUD | -22.863% |
| Tissue Repair Ltd | -5.77 Million AUD | -7.227% |
| AdAlta Limited | -5.3 Million AUD | -16.777% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 86.353% |
| Hexima Limited | -995.54 Thousand AUD | -522.008% |
| AnteoTech Limited | -11.57 Million AUD | 46.484% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 90.405% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 71.002% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -90.974% |
| Actinogen Medical Limited | -12.92 Million AUD | 52.076% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -226.327% |